ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Gilead picks Precision BioSciences as its second gene-editing partner

by Ryan Cross
September 15, 2018 | APPEARED IN VOLUME 96, ISSUE 37

 

Gilead Sciences is bolstering its gene-editing alliances—but not with companies using CRISPR. Instead, Gilead has picked Precision BioSciences as a partner to develop therapies that chop up the DNA of hepatitis B virus with Precision’s gene-editing system, called Arcus. Precision could receive up to $445 million in future payments during the collaboration. It’s the second time Gilead has opted for an alternative to CRISPR. In January, the drug company said it would use Sangamo Therapeutics’ zinc finger nuclease gene-editing tool for cancer therapies.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment